Laura E. Niklason - 18 Aug 2025 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Reporting relationship: President, CEO and Director, Director
Issuer ticker: HUMA
Reported as of: 18 Aug 2025
Net transaction value: -$3,733,191
SEC form: 4
Accepted by SEC: 20 Aug 2025, 19:29:04 UTC
Prior SEC filing: 16 Jun 2025
Next SEC filing: 17 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact

Key filing fact

Laura E. Niklason filed Form 4 for Humacyte, Inc. (HUMA) on 20 Aug 2025.

Key facts

This page summarizes Laura E. Niklason's Form 4 filing for Humacyte, Inc. (HUMA).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 20 Aug 2025, 19:29.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: -$3,733,191.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001878075 Primary reporting owner

Niklason Laura E

Relationship: President, CEO and Director, Director
Address: 2525 EAST NORTH CAROLINA, HIGHWAY 54, DURHAM
Signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Signature date: 20 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HUMA transaction

Common Stock

Sale

Transaction value: $1,005,329
Shares: -549,360
Change %: -25%
Price: $1.83
Shares after: 1,691,685
Date: 18 Aug 2025
Ownership: By Ayabudge LLC
Footnotes: F1, F2

HUMA transaction

Common Stock

Sale

Transaction value: $1,793,000
Shares: -1,100,000
Change %: -65%
Price: $1.63
Shares after: 591,685
Date: 19 Aug 2025
Ownership: By Ayabudge LLC
Footnotes: F1, F3

HUMA transaction

Common Stock

Sale

Transaction value: $934,862
Shares: -591,685
Change %: -100%
Price: $1.58
Shares after: 0
Date: 20 Aug 2025
Ownership: By Ayabudge LLC
Footnotes: F1, F4

HUMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 243,851
Date: 18 Aug 2025
Ownership: Direct

HUMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,148,240
Date: 18 Aug 2025
Ownership: By The Niklason Living Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.

Footnote F2

The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.79 to $1.92. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.57 to $1.76. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.53 to $1.69. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.